The tweet was deleted by the author.
But we saved everything 🙂.
Neurogene Inc. has announced plans to present new research on the rationale for intracerebroventricular (ICV) delivery in central nervous system (CNS)-targeted gene therapy at the upcoming American Society of Gene and Cell Therapy Annual Meeting.
The presentation aims to shed light on the potential effectiveness of ICV delivery methods in advancing gene therapies for neurological conditions. The company continues to advance its research in developing novel approaches for the treatment of CNS disorders through innovative delivery techniques.
Neurogene has recently expanded its executive team, naming Christy Shafer as Chief Commercial Officer. The company also added Christine Mikail to its board of directors, according to a prior announcement. These leadership changes support ongoing initiatives in CNS disorder research and development.